Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash & Current Investments: 2020-2025

Historic Cash & Current Investments for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $152.8 million.

  • Tango Therapeutics' Cash & Current Investments fell 47.90% to $152.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $808.2 million, marking a year-over-year decrease of 37.79%. This contributed to the annual value of $257.9 million for FY2024, which is 24.21% down from last year.
  • Latest data reveals that Tango Therapeutics reported Cash & Current Investments of $152.8 million as of Q3 2025, which was down 15.47% from $180.8 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Cash & Current Investments high stood at $506.1 million for Q3 2021, and its period low was $53.2 million during Q2 2021.
  • For the 3-year period, Tango Therapeutics' Cash & Current Investments averaged around $282.9 million, with its median value being $310.7 million (2023).
  • As far as peak fluctuations go, Tango Therapeutics' Cash & Current Investments spiked by 212,683.58% in 2021, and later plummeted by 47.90% in 2025.
  • Tango Therapeutics' Cash & Current Investments (Quarterly) stood at $487.5 million in 2021, then fell by 24.90% to $366.1 million in 2022, then dropped by 7.05% to $340.3 million in 2023, then dropped by 24.21% to $257.9 million in 2024, then crashed by 47.90% to $152.8 million in 2025.
  • Its Cash & Current Investments was $152.8 million in Q3 2025, compared to $180.8 million in Q2 2025 and $216.7 million in Q1 2025.